Federal Pharmaceutical International Holdings Limited is a listed company in Hong Kong, and its chairman, Cai Jinle, is a Hong Kong resident.
Federal Pharmaceuticals was established in Hong Kong in 199. In 1994, Zhuhai Federal Pharmaceutical Co., Ltd. was established with an investment of several hundred million Hong Kong dollars. With advanced pharmaceutical technology, scientific management and excellent service, and with the enthusiasm of serving the health of China people, it provided diversified products, especially antibiotic products, as well as raw materials and intermediates of such products, and made every effort to promote the development of medical and health undertakings in China. FedEx has six production bases, including Hong Kong FedEx Pharmaceutical Co., Ltd. (preparation), Zhuhai FedEx Pharmaceutical Co., Ltd. (raw material), Zhongshan Branch of Zhuhai FedEx Pharmaceutical Co., Ltd. (preparation), FedEx Jinyi Capsule Factory (hollow capsule), FedEx Pharmaceutical (Chengdu) Co., Ltd. (intermediate) and FedEx Pharmaceutical (Inner Mongolia) Co., Ltd. (intermediate). Federal Pharmaceutical integrates drug research and development, production and management, and integrates the production of pharmaceutical intermediates, raw materials, pharmaceutical preparations and packaging materials from biological fermentation, realizing a vertically integrated production and management model, and laying a solid foundation for the excellent product quality of Federal Pharmaceutical with a high-quality after-sales service network, a perfect market information feedback system and a rigorous quality assurance system. On June 15th, 27, Federal Pharmaceutical International Holdings Limited was successfully listed in Hong Kong, which marked that Federal Pharmaceutical stepped onto a new development platform and expanded a broad space for its foothold in Hong Kong, radiating the world and realizing the rapid expansion of corporate brands. Federal pharmaceutical has world-class production equipment. The annual production capacity is 1.5 billion capsules, 48 million tablets, 1 million bags of granules, 2 million bags of suspension, 3 million bottles of oral liquid, 3 million bottles of powder injection, 13 million ointments, 5 tons of freeze-dried raw materials, 15 million eye drops and 35 million injections, and the annual production capacity has jumped to a new level. Federal Pharmaceuticals has been leading in many products. The national torch plan key high-tech enterprises, Guangdong high-tech enterprises, China pharmaceutical professional Post-Doctoral Research Center, China pharmaceutical industry top 1, Guangdong advanced collective, each of which is well-known in the industry, fully proves the comprehensive strength of Federal Pharmaceuticals; The first batch of pharmaceutical enterprises in China that all dosage forms in the whole factory have passed the national GMP certification at one time, the research and development of more than 16 drugs, the acquisition of hundreds of medical approvals, and every valuable gold-lettered signboard fully reflect the leading level of federal pharmaceuticals. As always, Federal Pharmaceuticals adheres to the promise of "making life more valuable", and strives to promote the development of medical and health undertakings in China and provide more high-quality and efficient medical products for the society.